相关实验视频
Updated: Jan 15, 2026
05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
902
澳大利亚的tirezepatide支持的数字减肥计划的有效性和坚持:现实世界的观察研究
Louis Talay1, Jason Hom2, Tamara Scott2
1Faculty of Arts and Social Sciences, University of Sydney SDN, Camperdown, Sydney, New South Wales, Australia.
Diabetes, obesity & metabolism
|January 14, 2026
概括
蒂尔泽帕提德与数字减肥服务相结合显示,参与患者的体重显著减少. 然而,较低的坚持限制了整体有效性,强调了需要更好的参与策略.
科学领域:
- 内分泌学 在内分泌学.
- 代谢障碍 代谢障碍 代谢障碍
- 数字健康数字健康
背景情况:
- 肥胖是一个重大的全球健康挑战.
- 像提尔泽帕提德这样的药物疗法具有潜力,但需要综合生活方式支持.
- 支持这些治疗的数字减肥服务 (DWLS) 的现实数据有限.
研究的目的:
- 为了在澳大利亚的数字减肥服务中评估tirezepatide的现实有效性.
- 评估6个月和12个月的体重减轻,坚持率和结果预测因素.
- 确定影响药物DWLS患者参与和成功的因素.
主要方法:
- 一项对4309名患者的回顾性分析,这些患者通过Juniper AU DWLS开始服用tirezepatide.
- 患者数据包括人口统计,基线BMI,药物坚持和体重跟踪.
- 坚持被定义为药物订单和体重输入在6个月和12个月;结果分析使用最后的观察转移.
主要成果:
- 在6个月后,31.7%的患者仍然坚持,平均体重减轻了16.9%.
- 在12个月后,16.1%的人坚持,平均体重减轻22.7%.
- 早期减肥和持续参与 (体重跟踪,教练消息) 预测了更好的结果,而过度的早期跟踪显示了负相关性.
结论:
- 蒂尔泽帕提德与数字护理相结合,在参与的个体中实现了显著的体重减轻.
- 较低的坚持仍然是人口层面有效性的障碍.
- 早期反应和一致的参与至关重要;管理患者对早期减肥的期望是必要的.
相关概念视频
01:21Drug Dosing: Obese Patients
218
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
218
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
245
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
245
01:29Therapeutic Drug Monitoring: Affecting Factors
200
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
200
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
165
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
165